Furthermore, while evidence for Anlotinib’s efficacy in HER2-positive BC is still lacking, it has demonstrated significant antitumor activity and a favorable safety profile in various solid tumors, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (34, 35). This evidence concerns the gene ERBB2 and breast cancer.